^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Anluoqing (envonalkib)

    i
    Company:
    Shouyao Holdings, Sino Biopharm
    Drug class:
    ALK inhibitor, ROS1 inhibitor, c-MET inhibitor
    Related drugs:
    Apply
    Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules (NCT04675060)
    Phase 1
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    04/01/2021
    Initiation :
    02/23/2021
    Primary completion :
    03/01/2022
    Completion :
    03/01/2022
    ALK • MET • ROS1
    |
    MET amplification • ALK fusion • ALK mutation • ROS1 fusion • MET mutation • ALK-ROS1 fusion
    |
    Anluoqing (envonalkib)
    Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (NCT04056572)
    Phase 2
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Unknown status
    Last update posted :
    10/30/2019
    Initiation :
    08/13/2019
    Primary completion :
    10/30/2021
    Completion :
    04/30/2022
    ALK
    |
    ALK positive
    |
    Xalkori (crizotinib) • Anluoqing (envonalkib)
    Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) (NCT04009317)
    Phase 3
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Unknown status
    Last update posted :
    10/30/2019
    Initiation :
    08/13/2019
    Primary completion :
    10/30/2021
    Completion :
    04/30/2022
    ALK
    |
    ALK positive
    |
    Xalkori (crizotinib) • Anluoqing (envonalkib)